Clinical Trial Update: Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Pfizer-sponsored Phase 2 trial of an oral VEGFR-2 tyrosine kinase inhibitor for small-volume ovarian, peritoneal, and fallopian tube cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• VEGFR-2 tyrosine kinase inhibitor (unspecified)

Snippet

Sponsor: Pfizer | Conditions: Ovarian Neoplasms, Peritoneal Neoplasms | Phase 2 | Status: COMPLETED